IGF1 and cancer: Conversely, IF—especially when synchronized with circadian rhythm (i.e., TRF)—may mitigate cancer risk by attenuating insulin/IGF‐1/mTOR signaling, eliciting an anticancer proteomic profile without imposing severe energy deficit, enhancing metabolic homeostasis by reducing glucose availability, IGF‐1, and insulin; reducing TNF‐alpha and IL‐1‐beta; and restoring circadian integrity as indicated in several gene expression analyses (Salvadori et al. 2021; Tiwari et al. 2022; Godos et al. 2025).